Drug intelligence / Profile preview

anti-dengue monoclonal antibody

Development stage: Preclinical
Lead developer: Techinvention Lifecare
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Anti-dengue monoclonal antibody is a biotherapeutic candidate being developed by Techinvention Lifecare for the treatment and prevention of Dengue fever. Discovered using phage display technology, this monoclonal antibody is designed to bind to and neutralize the Dengue virus, thereby preventing viral entry and replication in host cells. The program is currently in the proof-of-concept stage of preclinical development, aiming to address the significant global health burden of Dengue virus infections through a targeted immunological approach.

Other names: Anti-Dengue mAb

Targets

E (Tick-borne encephalitis virus envelope protein)

Beyond the preview

Go deeper on anti-dengue monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-dengue monoclonal antibody.

Explore the full profile